Avanos Medical (AVNS)
(Delayed Data from NYSE)
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
Zacks News
LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 5th
by Zacks Equity Research
AVNS, NKE and PLAB have been added to the Zacks Rank #5 (Strong Sell) List on October 5, 2022.
New Strong Sell Stocks for September 28th
by Zacks Equity Research
AVNS, ARCE and DCO have been added to the Zacks Rank #5 (Strong Sell) List on September 28, 2022.
Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
by Zacks Equity Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.13% and 2.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Q2 Earnings Miss Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -11.86% and 1.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
Can Avanos Medical (AVNS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Tandem Diabetes Care, Inc. (TNDM) Soars 6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.
HCA Healthcare (HCA) Q1 Earnings Miss, Trims '22 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results reflect elevated expenses related to salaries and benefits, partly offset by an uptick in revenues driven by higher patient admissions.
Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.
Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued strength across its business segments.
Anthem (ANTM) Q1 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Anthem's (ANTM) first-quarter results indicate solid top-line growth and strong contribution from each of its businesses, partly offset by higher expenses.